| Cigna EviCore | MOL.CU.109.A: Genetic Testing for Cancer Susceptibility and Hereditary Cancer Syndromes | 2026-01-01 |
| Cigna EviCore | MOL.CU.110.A: Genetic Testing for Carrier Status | 2026-01-01 |
| Cigna EviCore | MOL.CU.111.A: Genetic Testing for Non-Medical Purposes | 2026-01-01 |
| Cigna EviCore | MOL.CU.112.A: Genetic Testing for Prenatal Screening and Diagnostic Testing | 2026-01-01 |
| Cigna EviCore | MOL.CU.113.A: Genetic Testing for the Screening, Diagnosis, and Monitoring of Cancer | 2026-01-01 |
| Cigna EviCore | MOL.CU.114.A: Genetic Testing to Diagnose Non-Cancer Conditions | 2026-01-01 |
| Cigna EviCore | MOL.CU.115.A: Genetic Testing to Predict Disease Risk | 2026-01-01 |
| Cigna EviCore | MOL.CU.116.A: Genetic Testing by Multigene Panels | 2026-01-01 |
| Cigna EviCore | MOL.CU.117.A: Experimental, Investigational, or Unproven Laboratory Testing | 2026-01-01 |
| Cigna EviCore | MOL.CU.118.A: Pharmacogenomic Testing for Drug Toxicity and Response | 2026-01-01 |